Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Inge Marie Svane
Center for Cancer Immune Therapy, University Hospital Herlev,
Herlev Ringvej 75, DK-2730 Herlev
Denmark
Research Article
Influence of Metronomic Cyclophosphamide and Interleukine-2 alone or Combined on Blood Regulatory T Cells in Patients with Advanced Malignant Melanoma Treated with Dendritic Cell Vaccines
Author(s): Lotte Engell-Noerregaard, Eva Ellebaek, Trine Zeeberg Iversen, Troels Holz Hansen, Marie K Brimnes, Özcan Met, Jon Bjoern, Mads Hald Andersen, Per thor Straten and Inge Marie SvaneLotte Engell-Noerregaard, Eva Ellebaek, Trine Zeeberg Iversen, Troels Holz Hansen, Marie K Brimnes, Özcan Met, Jon Bjoern, Mads Hald Andersen, Per thor Straten and Inge Marie Svane
Background: Interleukine-2 and Cyclophosphamide are known to influence the circulating T cells and are used for immune manipulation in cancer patients. We analyzed the influence on the Treg population in three different dendritic cell (DC) vaccine trials including either concurrent interleukine-2 (IL-2), combined IL-2 and metronomic Cyclophosphamide (MCy), or only MCy.Methods: Melanoma patients received treatment with autologous DCs. IL-2 was applied in trial I and II and MCy was applied in trial I and III. Flowcytometry analysis was performed on fresh drawn blood-samples measuring CD4, CD25 and CD127.Results: In the trials where IL-2 was applied a marked increase in the proportion of CD4+CD25+CD127- Tregs from baseline to the 4th vaccine was observed. This was followed by a decr.. View More»
DOI:
10.4172/2155-9899.1000118